Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas
JAMA Network Open · 2023
DOI: 10.1001/jamanetworkopen.2022.53285 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, 2023. Verfasst von Chengcheng Guo und 43 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery and Neuro-oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative I…. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioma. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Importance High-grade gliomas (HGGs) constitute the most common and aggressive primary brain tumor, with 5-year survival rates of 30.9% for grade 3 gliomas and 6.6% for grade 4 gliomas. The add-on efficacy of interferon alfa is unclear for the treatment of HGG.
Objectives
To compare the therapeutic efficacy and toxic effects of the combination of temozolomide and interferon alfa and temozolomide alone in patients with newly diagnosed HGG. Design, Setting, and Participants This multicenter, randomized, phase 3 clinical trial enrolled 199 patients with newly diagnosed HGG from May 1, 2012, to March 30, 2016, at 15 Chinese medical centers. Follow-up was completed July 31, 2021, and data were analyzed from September 13 to November 24, 2021. Eligible patients were aged 18 to 75 years with newly diagnosed and histologically confirmed HGG and had received no prior chemotherapy, radiotherapy, or immunotherapy for their HGG.
Interventions
All patients received standard radiotherapy concurrent with temozolomide. After a 4-week break, patients in the temozolomide with interferon alfa group received standard temozolomide combined with interferon alfa every 28 days. Patients in the temozolomide group received standard temozolomide. Main Outcomes and Measures The primary end point was 2-year overall survival (OS). Secondary end points were 2-year progression-free survival (PFS) and treatment tolerability.
Results
A total of 199 patients with HGG were enrolled, with a median follow-up time of 66.0 (95% CI, 59.1-72.9) months. Seventy-nine patients (39.7%) were women and 120 (60.3%) were men, with ages ranging from 18 to 75 years and a median age of 46.9 (95% CI, 45.3-48.7) years. The median OS of patients in the temozolomide plus interferon alfa group (26.7 [95% CI, 21.6-31.7] months) was significantly longer than that in the standard group (18.8 [95% CI, 16.9-20.7] months; hazard ratio [HR], 0.64 [95% CI, 0.47-0.88]; P = .005). Temozolomide plus interferon alfa also significantly improved median OS in patients with O6-methylguanine-DNA methyltransferase (MGMT) unmethylation (24.7 [95% CI, 20.5-28.8] months) compared with temozolomide (17.4 [95% CI, 14.1-20.7] months; HR, 0.57 [95% CI, 0.37-0.87]; P = .008). Seizure and influenzalike symptoms were more common in the temozolomide plus interferon alfa group, with 2 of 100 (2.0%) and 5 of 100 (5.0%) patients with grades 1 and 2 toxic effects, respectively ( P = .02). Finally, results suggested that methylation level at the IFNAR1/2 promoter was a marker of sensitivity to temozolomide plus interferon alfa. Conclusions and Relevance Compared with the standard regimen, temozolomide plus interferon alfa treatment could prolong the survival time of patients with HGG, especially the MGMT promoter unmethylation variant, and the toxic effects remained tolerable. Trial Registration ClinicalTrials.gov Identifier: NCT01765088
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery and Neuro-oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
- Department of Radiation, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
- Department of Neurosurgery, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, China.
- Department of Neuro-oncology, Guangdong Sanjiu Brain Hospital, Guangzhou, China.
- Department of Clinical Research, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
- Department of Pathology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
Zitieren
APA
Guo, C., Yang, Q., Xu, P., Deng, M., Jiang, T., Cai, L., Li, J., Sai, K., Xi, S., Ouyang, H., Liu, M., Li, X., Li, Z., Ni, X., Cao, X., Li, C., Wu, S., Du, X., Su, J., …, & Chen, Z. (2023). Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2022.53285
Vancouver
Guo C, Yang Q, Xu P, Deng M, Jiang T, Cai L, et al. Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas. JAMA Network Open. 2023. doi:10.1001/jamanetworkopen.2022.53285
BibTeX
@article{Guo2023,
author = {Guo, Chengcheng and Yang, Qunying and Xu, Pengfei and Deng, Meiling and Jiang, Taipeng and Cai, Linbo and Li, Jibin and Sai, Ke and Xi, Shaoyan and Ouyang, Hui and Liu, Mingfa and Li, Xianming and Li, Zihuang and Ni, Xiangrong and Cao, Xi and Li, Cong and Wu, Shaoxiong and Du, Xiaojing and Su, Jun and Xue, Xiaoying and Wang, Yiming and Li, Gang and Qin, Zhiyong and Yang, Hui and Zhou, Tao and Liu, Jinquan and Hu, Xuefeng and Wang, Jian and Jiang, Xiaobing and Lin, Fuhua and Zhang, Xiangheng and Ke, Chao and Lv, Xiaofei and Lv, Yanchun and Hu, Wanming and Zeng, Jing and Chen, Zhenghe and Zhong, Sheng and Wang, Hairong and Chen, Yinsheng and Zhang, Ji and Li, Depei and Mou, Yonggao and Chen, Zhongping},
title = {Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas},
journal = {JAMA Network Open},
year = {2023},
doi = {10.1001/jamanetworkopen.2022.53285}
}
EUVIMED